A multilectin affinity approach for comparative glycoprotein profiling of rheumatoid arthritis and spondyloarthropathy

Clinical Proteomics

Akhilesh Pandey⁶  Subramanian Shankar⁹  Ramesh Jois¹  H C Harsha⁷  T S Keshava Prasad⁴  Bipin Nair⁸  Nirujogi Raja Sekhar⁴  Sneha M Pinto³  Renu Verma⁷  Shantal Tankala Gupta⁹  Jayshree Advani⁷  Santosh Renuse⁸  Lavanya Balakrishnan⁵  Renu Goel⁵  Rakesh Sharma²  Mitali Bhattacharjee⁸ 

[1] Department of Rheumatology, Fortis Hospital, Bangalore 560076, India;Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences, Bangalore 560029, India;Manipal University, Madhav Nagar, Manipal 576104, India;Centre of Excellence in Bioinformatics, Bioinformatics Centre, School of Life Sciences, Pondicherry University, Puducherry 605 014, India;Department of Biotechnology, Kuvempu University, Shankaraghatta 577451, India;McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA;Institute of Bioinformatics, International Technology Park, Bangalore 560066, India;Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;Department of Internal Medicine, Armed Forces Medical College, Pune 411040, India

关键词: Biomarkers;    Synovium;    Endothelial dysfunction;    Prognostic marker;    Pannus;   

Others  :  1026339
DOI  :  10.1186/1559-0275-10-11

 received in 2013-04-30, accepted in 2013-08-11,  发布年份 2013

【 摘 要 】

Background

Arthritis refers to inflammation of joints and includes common disorders such as rheumatoid arthritis (RA) and spondyloarthropathies (SpAs). These diseases differ mainly in terms of their clinical manifestations and the underlying pathogenesis. Glycoproteins in synovial fluid might reflect the disease activity status in the joints affected by arthritis; yet they have not been systematically studied previously. Although markers have been described for assisting in the diagnosis of RA, there are currently no known biomarkers for SpA.

Materials and methods

We sought to determine the relative abundance of glycoproteins in RA and SpA by lectin affinity chromatography coupled to iTRAQ labeling and LC-MS/MS analysis. We also used ELISA to validate the overexpression of VCAM-1, one of the candidate proteins identified in this study, in synovial fluid from RA patients.

Results and discussion

We identified proteins that were previously reported to be overexpressed in RA including metalloproteinase inhibitor 1 (TIMP1), myeloperoxidase (MPO) and several S100 proteins. In addition, we discovered several novel candidates that were overexpressed in SpA including Apolipoproteins C-II and C-III and the SUN domain-containing protein 3 (SUN3). Novel molecules found overexpressed in RA included extracellular matrix protein 1 (ECM1) and lumican (LUM). We validated one of the candidate biomarkers, vascular cell adhesion molecule 1 (VCAM1), in 20 RA and SpA samples using ELISA and confirmed its overexpression in RA (p-value <0.01). Our quantitative glycoproteomic approach to study arthritic disorders should open up new avenues for additional proteomics-based discovery studies in rheumatological disorders.

【 授权许可】

   
2013 Bhattacharjee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hadjidakis DJ, Androulakis II: Bone remodeling. Ann NY Acad Sci 2006, 1092:385-396.
• [2]Walsh NC, Gravallese EM: Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010, 233:301-312.
• [3]Schett G: Joint remodelling in inflammatory disease. Ann Rheum Dis 2007, 66(Suppl 3):iii42-iii44.
• [4]Gough AK, Lilley J, Eyre S, Holder RL, Emery P: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.
• [5]Rothschild BM: What is this disease we call spondyloarthropathy? Clin Exp Rheumatol 2003, 21:283-285.
• [6]Akdeniz O, Alayli G, Tosun FC, Diren B, Cengiz K, Selcuk MB, Sunter T, Canturk F: Early spondyloarthropathy: scintigraphic, biological, and clinical findings in MRI-positive patients. Clin Rheumatol 2008, 27:469-474.
• [7]Baeten D, De Keyser F: The histopathology of spondyloarthropathy. Curr Mol Med 2004, 4:1-12.
• [8]Mellana WM, Aronow WS, Palaniswamy C, Khera S: Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy. Curr Pharm Des 2012, 18:1450-1456.
• [9]Bakland G, Gran JT, Nossent JC: Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011, 70:1921-1925.
• [10]Tsybul’ko SV, Baranov AA, Korshunov NI, Kirdianov S, Abaitova NE, Borisova OL: Clinico-immunological aspects of renal lesions in rheumatoid arthritis. Klin Med (Mosk) 2001, 79:52-57.
• [11]Haroon M, Adeeb F, Devlin J, D OG , Walker F: A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis. Int J Rheum Dis 2011, 14:255-260.
• [12]Ruiz-Romero C, Calamia V, Carreira V, Mateos J, Fernandez P, Blanco FJ: Strategies to optimize two-dimensional gel electrophoresis analysis of the human joint proteome. Talanta 2010, 80:1552-1560.
• [13]Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R: Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001, 47:1089-1093.
• [14]Novak S: The early diagnosis of spondyloarthritis. Reumatizam 2011, 58:47-50.
• [15]Firth J: Rheumatoid arthritis: diagnosis and multidisciplinary management. Br J Nurs 2011, 20:1179-1180. 1182, 1184–1175
• [16]Venugopal A, Chaerkady R, Pandey A: Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders. Ann Indian Acad Neurol 2009, 12:3-11.
• [17]Gronborg M, Bunkenborg J, Kristiansen TZ, Jensen ON, Yeo CJ, Hruban RH, Maitra A, Goggins MG, Pandey A: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 2004, 3:1042-1055.
• [18]Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, Dominiczak A, Mischak H: Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 2007, 6:4549-4555.
• [19]White RK: The rheology of synovial fluid. J Bone Joint Surg Am 1963, 45:1084-1090.
• [20]Levick JR: Microvascular architecture and exchange in synovial joints. Microcirculation 1995, 2:217-233.
• [21]Smith MD: The normal synovium. Open Rheumatol J 2011, 5:100-106.
• [22]Jay GD, Torres JR, Warman ML, Laderer MC, Breuer KS: The role of lubricin in the mechanical behavior of synovial fluid. Proc Natl Acad Sci USA 2007, 104:6194-6199.
• [23]Schurz J, Ribitsch V: Rheology of synovial fluid. Biorheology 1987, 24:385-399.
• [24]Conrozier T, Mathieu P, Vignon E, Piperno M, Rinaudo M: Differences in the osteoarthritic synovial fluid composition and rheology between patients with or without flare: a pilot study. Clin Exp Rheumatol 2012, 30:729-734.
• [25]Nettelbladt E, Sundblad L: On the acid glycoproteins of serum and synovial fluid in rheumatoid arthritis. Arthritis Rheum 1961, 4:161-168.
• [26]Pan S, Chen R, Aebersold R, Brentnall TA: Mass spectrometry based glycoproteomics--from a proteomics perspective. Mol Cell Proteomics 2011, 10:R110 003251.
• [27]Schiess R, Wollscheid B, Aebersold R: Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009, 3:33-44.
• [28]Kucharz E, Drozdz M, Gburek Z, Olczyk K, Machej M, Rendecka M: Serum glycoproteins and synovial fluid in seropositive and seronegative rheumatoid arthritis. Med Interne 1984, 22:253-257.
• [29]Kulkarni AV, Engineer JJ, Sequira RD, Borges NE, Joshi VR: Glycoproteins as markers of inflammation in rheumatic disorders. J Postgrad Med 1986, 32:89-93.
• [30]Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O’Meally RN, et al.: TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol Cell Proteomics 2012, 11:M112 017764.
• [31]Raghothama C, Pandey A: Absolute systems biology–measuring dynamics of protein modifications. Trends Biotechnol 2003, 21:467-470.
• [32]Chaerkady R, Thuluvath PJ, Kim MS, Nalli A, Vivekanandan P, Simmers J, Torbenson M, Pandey A: O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma. Clin Proteomics 2008, 4:137-155.
• [33]Polisetty RV, Gautam P, Sharma R, Harsha HC, Nair SC, Gupta MK, Uppin MS, Challa S, Puligopu AK, Ankathi P, et al.: LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol Cell Proteomics 2012, 11:M111 013565.
• [34]Kaur H, Halliwell B: Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 1994, 350:9-12.
• [35]Raouf A, Ganss B, McMahon C, Vary C, Roughley PJ, Seth A: Lumican is a major proteoglycan component of the bone matrix. Matrix Biol 2002, 21:361-367.
• [36]Onda M, Ishiwata T, Kawahara K, Wang R, Naito Z, Sugisaki Y: Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. Exp Mol Pathol 2002, 72:142-149.
• [37]Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown AM, Iozzo RV: Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem 2003, 278:17491-17499.
• [38]Botney MD, Kaiser LR, Cooper JD, Mecham RP, Parghi D, Roby J, Parks WC: Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol 1992, 140:357-364.
• [39]Chang X, Jian X, Yan X: Expression and citrullination of keratin in synovial tissue of rheumatoid arthritis. Rheumatol Int 2009, 29:1337-1342.
• [40]Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H, Chazin WJ, Nakatani Y, Yui S, Makino H: The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R69. BioMed Central Full Text
• [41]Perera C, McNeil HP, Geczy CL: S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol 2010, 88:41-49.
• [42]Steenvoorden MM, Toes RE, Ronday HK, Huizinga TW, Degroot J: RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro. Clin Exp Rheumatol 2007, 25:740-742.
• [43]Moller B, Kessler U, Braner A, Dielehner N, Kaltwasser JP: [Analysis of immunoglobulins and complement factors in synovial fluid and serum in rheumatoid arthritis, seronegative spondyloarthropathies and osteoarthritis: pathophysiology and retrospective analysis of clinical value]. Z Rheumatol 2002, 61:48-57.
• [44]Brinch L, Vinje O, Teisberg P, Mellbye OJ, Aakesson I: The in-vivo metabolism of C3 in ankylosing spondylitis. Ann Rheum Dis 1982, 41:86-89.
• [45]Sheitanov I, Nikolov K, Petrova P: [CH50, C3 and C4 in the serum and synovial fluid of rheumatoid arthritis patients]. Vutr Boles 1987, 26:66-70.
• [46]Dunkelberger JR, Song WC: Role and mechanism of action of complement in regulating T cell immunity. Mol Immunol 2010, 47:2176-2186.
• [47]Yasuda T: Hyaluronan inhibits p38 mitogen-activated protein kinase via the receptors in rheumatoid arthritis chondrocytes stimulated with fibronectin fragment. Clin Rheumatol 2010, 29:1259-1267.
• [48]Hughes DE, Salter DM, Simpson R: CD44 expression in human bone: a novel marker of osteocytic differentiation. J Bone Miner Res 1994, 9:39-44.
• [49]Edwards SW, Hughes V, Barlow J, Bucknall R: Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis. Biochem J 1988, 250:81-85.
• [50]Laursen NS, Magnani F, Gottfredsen RH, Petersen SV, Andersen GR: Structure, function and control of complement C5 and its proteolytic fragments. Curr Mol Med 2012, 12:1083-1097.
• [51]Kriegsmann J, Keyszer GM, Geiler T, Brauer R, Gay RE, Gay S: Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid synovium demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 1995, 72:209-214.
• [52]Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J: Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002, 61:804-809.
• [53]Navarro-Hernandez RE, Oregon-Romero E, Vazquez-Del Mercado M, Rangel-Villalobos H, Palafox-Sanchez CA, Munoz-Valle JF: Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity: association with genetic polymorphisms. Dis Markers 2009, 26:119-126.
• [54]Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995, 376:517-519.
• [55]Braun M, Pietsch P, Felix SB, Baumann G: Modulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 on human coronary smooth muscle cells by cytokines. J Mol Cell Cardiol 1995, 27:2571-2579.
• [56]Sidibe A, Mannic T, Arboleas M, Subileau M, Gulino-Debrac D, Bouillet L, Jan M, Vandhuick T, Le Loet X, Vittecoq O, Vilgrain I: Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor alpha-induced VE-cadherin cleavage. Arthritis Rheum 2012, 64:77-87.
• [57]Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA: Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996, 78:161-171.
• [58]Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006, 45:414-420.
• [59]Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S: MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2004, 22:335-338.
• [60]Tzur YB, Wilson KL, Gruenbaum Y: SUN-domain proteins: ‘Velcro’ that links the nucleoskeleton to the cytoskeleton. Nat Rev Mol Cell Biol 2006, 7:782-788.
• [61]Zdrojewski Z: Amyloidosis in rheumatic diseases. Ann Acad Med Stetin 2010, 56(1):7-15.
• [62]Lange U, Boss B, Teichmann J, Klor HU, Neeck G: Serum amyloid A–an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000, 19:119-122.
• [63]Fischer R, Trudgian DC, Wright C, Thomas G, Bradbury LA, Brown MA, Bowness P, Kessler BM: Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Mol Cell Proteomics 2012, 11:M111 013904.
• [64]Prete PE, Gurakar-Osborne A, Kashyap ML: Synovial fluid lipids and apolipoproteins: a contemporary perspective. Biorheology 1995, 32:1-16.
• [65]Kamper EF, Kopeikina LT, Trontzas P, Kyriazis NC, Vaiopoulos G, Stavridis J: Comparative study of tetranectin levels in serum and synovial fluid of patients with rheumatoid arthritis, seronegative spondylarthritis and osteoarthritis. Clin Rheumatol 1998, 17:318-324.
• [66]Fairney A, Straffen AM, May C, Seifert MH: Vitamin D metabolites in synovial fluid. Ann Rheum Dis 1987, 46:370-374.
• [67]Kawai N, Matsumoto H: Vitamin-D binding protein levels in liver cirrhosis, chronic hepatitis, and rheumatoid arthritis. Nihon Hoigaku Zasshi 1984, 38:797-803.
• [68]Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I: Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011, 26:1609-1616.
• [69]Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, Michel BA, Gay RE, Liu FT, Gay S, Neidhart M: Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003, 48:2788-2795.
• [70]Postigo AA, Garcia-Vicuna R, Diaz-Gonzalez F, Arroyo AG, De Landazuri MO, Chi-Rosso G, Lobb RR, Laffon A, Sanchez-Madrid F: Increased binding of synovial T lymphocytes from rheumatoid arthritis to endothelial-leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1). J Clin Invest 1992, 89:1445-1452.
• [71]Dessein PH, Joffe BI, Singh S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R634-R643. BioMed Central Full Text
• [72]Saroha A, Kumar S, Chatterjee BP, Das HR: Jacalin Bound Plasma O-Glycoproteome and Reduced Sialylation of Alpha 2-HS Glycoprotein (A2HSG) in Rheumatoid Arthritis Patients. PLoS One 2012, 7:e46374.
• [73]Barbhuiya MA, Sahasrabuddhe NA, Pinto SM, Muthusamy B, Singh TD, Nanjappa V, Keerthikumar S, Delanghe B, Harsha HC, Chaerkady R, et al.: Comprehensive proteomic analysis of human bile. Proteomics 2011, 11:4443-4453.
• [74]Mathivanan S, Pandey A: Human Proteinpedia as a resource for clinical proteomics. Mol Cell Proteomics 2008, 7:2038-2047.